Loading clinical trials...

A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease | Clinical Trials | Clareo Health

RECRUITING

A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

A Real-world, Prospective, Observational Study Assessing the Effectiveness of Repatha® Used in Combination With Standard of Care Compared With Standard of Care Alone on Major Cardiovascular Events in Chinese Patients With Established Atherosclerotic Cardiovascular Disease

NCT06295679•Amgen

View on ClinicalTrials.gov

Summary

The primary objective of the study is to evaluate real-world effectiveness of treatment with Repatha® in combination with SOC, compared with SOC alone, on the risk for cardiovascular (CV) death, myocardial infarction (MI), stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in participants with established atherosclerotic CV disease (ASCVD) treated with SOC, according to local clinical practice.

Eligibility

Age

18 - 150 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult participants ≥ 18 years of age.
•Participants or participant's legally authorized representative has provided informed consent to participate in this study.
•Participants who meet one of the following:
•Prescribed Repatha® in addition to an existing SOC treatment according to local guidelines and approved label.
•OR
•Already received SOC treatment prior to enrollment.
•Participants with ANY of the following.
•Diagnosis of MI OR stroke within 2 years before enrollment.
•2 MIs OR ≥ 2 strokes OR (≥ 1 MI AND ≥ 1 stroke) any time before enrollment.
•Diagnosis of (MI OR stroke) AND diabetes.
+4 more criteria